Toulouse, France

Karim Bedjeguelal

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 7.1

ph-index = 2

Forward Citations = 51(Granted Patents)


Company Filing History:


Years Active: 2013-2016

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations of Karim Bedjeguelal

Introduction

Karim Bedjeguelal is a notable inventor based in Toulouse, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for cancer treatment. With a total of five patents to his name, his work reflects a commitment to advancing medical science.

Latest Patents

One of his latest patents involves derivatives of azaindazole or diazaindazole type for treating cancers that overexpress Trk proteins. This invention relates to a compound of a specific formula, which can be used in pharmaceutical compositions aimed at treating such cancers. Another significant patent focuses on tri- and tetracyclic pyrazolo[3,4-B]pyridine compounds, which serve as antineoplastic agents. This patent details the general formula of these compounds and their various forms, including pharmaceutically acceptable salts and stereoisomers.

Career Highlights

Throughout his career, Karim has worked with prominent companies in the pharmaceutical industry, including Pierre Fabre Medicament. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to the advancement of cancer treatment options.

Collaborations

Karim has collaborated with several professionals in his field, including Rémi Rabot and El Bachir Kaloun. These partnerships have likely enhanced his research and development efforts, leading to successful patent applications.

Conclusion

Karim Bedjeguelal's contributions to pharmaceutical innovations, particularly in cancer treatment, highlight his role as a significant inventor in the industry. His patents reflect a dedication to improving medical outcomes for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…